Close

move up move left move right move bottom

Thank You for Registering

XARELTO® for Healthcare Professionals is your one-stop shop for comprehensive information and news about XARELTO®, the first oral, selective Factor Xa inhibitor with 6 indications approved by the FDA. Please be sure to add admin@info.janssen.com to your approved list of senders. We look forward to sharing more exciting news about XARELTO® with you shortly.

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.